JP2018537403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537403A5 JP2018537403A5 JP2018513463A JP2018513463A JP2018537403A5 JP 2018537403 A5 JP2018537403 A5 JP 2018537403A5 JP 2018513463 A JP2018513463 A JP 2018513463A JP 2018513463 A JP2018513463 A JP 2018513463A JP 2018537403 A5 JP2018537403 A5 JP 2018537403A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- group
- groups
- alkyl
- alkanediyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000412 dendrimer Substances 0.000 claims description 84
- 229920000736 dendritic polymer Polymers 0.000 claims description 84
- 125000005647 linker group Chemical group 0.000 claims description 72
- 229910052739 hydrogen Inorganic materials 0.000 claims description 53
- 239000001257 hydrogen Substances 0.000 claims description 53
- 125000000217 alkyl group Chemical group 0.000 claims description 52
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 46
- 125000003282 alkyl amino group Chemical group 0.000 claims description 44
- 150000002431 hydrogen Chemical class 0.000 claims description 44
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 36
- -1 amino, hydroxy Chemical group 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 29
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 150000002632 lipids Chemical class 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 108020004414 DNA Proteins 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 150000003431 steroids Chemical class 0.000 claims description 9
- 125000004434 sulfur atom Chemical group 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 108091079001 CRISPR RNA Proteins 0.000 claims description 6
- 108020004566 Transfer RNA Proteins 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 4
- 108020005004 Guide RNA Proteins 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 4
- 125000005265 dialkylamine group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000002679 microRNA Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 108091007428 primary miRNA Proteins 0.000 claims description 2
- 239000002924 silencing RNA Substances 0.000 claims description 2
- 125000000732 arylene group Chemical group 0.000 claims 19
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 0 CCCCCC(CCCCC[C@@]1*CC(C)C1)=C[C@@](C)C*CCC1CCC1 Chemical compound CCCCCC(CCCCC[C@@]1*CC(C)C1)=C[C@@](C)C*CCC1CCC1 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 150000002390 heteroarenes Chemical class 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 150000003973 alkyl amines Chemical group 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- ARAZOETUQJGUOY-UHFFFAOYSA-N CCCCCNCCN Chemical compound CCCCCNCCN ARAZOETUQJGUOY-UHFFFAOYSA-N 0.000 description 1
- WBKNTZBBWJPZOU-UHFFFAOYSA-N CCCCN1CCN(CCCN)CC1 Chemical compound CCCCN1CCN(CCCN)CC1 WBKNTZBBWJPZOU-UHFFFAOYSA-N 0.000 description 1
- XIMKUWSDNMPOGO-UHFFFAOYSA-N CCN(C)CCC(C)CN Chemical compound CCN(C)CCC(C)CN XIMKUWSDNMPOGO-UHFFFAOYSA-N 0.000 description 1
- OMKZWUPRGQMQJC-UHFFFAOYSA-N CN(C)CCCNCCCN Chemical compound CN(C)CCCNCCCN OMKZWUPRGQMQJC-UHFFFAOYSA-N 0.000 description 1
- KMBPCQSCMCEPMU-UHFFFAOYSA-N CN(CCCN)CCCN Chemical compound CN(CCCN)CCCN KMBPCQSCMCEPMU-UHFFFAOYSA-N 0.000 description 1
- RGUABPVONIGVAT-UHFFFAOYSA-N CN1CCN(CCCN)CC1 Chemical compound CN1CCN(CCCN)CC1 RGUABPVONIGVAT-UHFFFAOYSA-N 0.000 description 1
- FGVPCGSDRQMLTB-UHFFFAOYSA-N CNCCC1N(C)CCC1 Chemical compound CNCCC1N(C)CCC1 FGVPCGSDRQMLTB-UHFFFAOYSA-N 0.000 description 1
- PQYGBJHVVYREGU-UHFFFAOYSA-N CNCCCN(C)CCCNC Chemical compound CNCCCN(C)CCCNC PQYGBJHVVYREGU-UHFFFAOYSA-N 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZAXCZCOUDLENMH-UHFFFAOYSA-N NCCCNCCCNCCCN Chemical compound NCCCNCCCNCCCN ZAXCZCOUDLENMH-UHFFFAOYSA-N 0.000 description 1
- GHKSKVKCKMGRDU-UHFFFAOYSA-N NCCCNCCO Chemical compound NCCCNCCO GHKSKVKCKMGRDU-UHFFFAOYSA-N 0.000 description 1
- CXNQJNPKMZRHBC-UHFFFAOYSA-N NCCNCCN1CCN(CCN)CC1 Chemical compound NCCNCCN1CCN(CCN)CC1 CXNQJNPKMZRHBC-UHFFFAOYSA-N 0.000 description 1
- FAGUFWYHJQFNRV-UHFFFAOYSA-N NCCNCCNCCNCCN Chemical compound NCCNCCNCCNCCN FAGUFWYHJQFNRV-UHFFFAOYSA-N 0.000 description 1
- KZXOUIOAKUWAKB-UHFFFAOYSA-N NCCOCCCOCCN Chemical compound NCCOCCCOCCN KZXOUIOAKUWAKB-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- PLZVEHJLHYMBBY-UHFFFAOYSA-N Tetradecylamine Chemical compound CCCCCCCCCCCCCCN PLZVEHJLHYMBBY-UHFFFAOYSA-N 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- LAWOZCWGWDVVSG-UHFFFAOYSA-N dioctylamine Chemical compound CCCCCCCCNCCCCCCCC LAWOZCWGWDVVSG-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- GMTCPFCMAHMEMT-UHFFFAOYSA-N n-decyldecan-1-amine Chemical compound CCCCCCCCCCNCCCCCCCCCC GMTCPFCMAHMEMT-UHFFFAOYSA-N 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical group CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021181987A JP7496808B2 (ja) | 2015-09-14 | 2021-11-08 | リポカチオン性デンドリマーおよびその使用 |
| JP2024085967A JP2024122997A (ja) | 2015-09-14 | 2024-05-28 | リポカチオン性デンドリマーおよびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562218412P | 2015-09-14 | 2015-09-14 | |
| US62/218,412 | 2015-09-14 | ||
| PCT/US2016/051648 WO2017048789A1 (en) | 2015-09-14 | 2016-09-14 | Lipocationic dendrimers and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021181987A Division JP7496808B2 (ja) | 2015-09-14 | 2021-11-08 | リポカチオン性デンドリマーおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537403A JP2018537403A (ja) | 2018-12-20 |
| JP2018537403A5 true JP2018537403A5 (enExample) | 2019-10-24 |
| JP7041616B2 JP7041616B2 (ja) | 2022-03-24 |
Family
ID=58289845
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513463A Active JP7041616B2 (ja) | 2015-09-14 | 2016-09-14 | リポカチオン性デンドリマーおよびその使用 |
| JP2021181987A Active JP7496808B2 (ja) | 2015-09-14 | 2021-11-08 | リポカチオン性デンドリマーおよびその使用 |
| JP2024085967A Pending JP2024122997A (ja) | 2015-09-14 | 2024-05-28 | リポカチオン性デンドリマーおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021181987A Active JP7496808B2 (ja) | 2015-09-14 | 2021-11-08 | リポカチオン性デンドリマーおよびその使用 |
| JP2024085967A Pending JP2024122997A (ja) | 2015-09-14 | 2024-05-28 | リポカチオン性デンドリマーおよびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (9) | US11247968B2 (enExample) |
| EP (2) | EP3349802B1 (enExample) |
| JP (3) | JP7041616B2 (enExample) |
| KR (2) | KR102641298B1 (enExample) |
| CN (2) | CN116640316A (enExample) |
| CA (1) | CA2998473A1 (enExample) |
| CY (1) | CY1125338T1 (enExample) |
| DK (1) | DK3349802T3 (enExample) |
| ES (1) | ES2899308T3 (enExample) |
| PT (1) | PT3349802T (enExample) |
| WO (1) | WO2017048789A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116640316A (zh) * | 2015-09-14 | 2023-08-25 | 得克萨斯州大学系统董事会 | 亲脂阳离子树枝状聚合物及其用途 |
| CN109069440A (zh) * | 2016-03-02 | 2018-12-21 | 得克萨斯州大学系统董事会 | 用于免疫治疗的激活sting的纳米疫苗 |
| PL3458074T3 (pl) | 2016-05-16 | 2024-11-12 | Board Of Regents Of The University Of Texas System | KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA |
| US11235067B2 (en) * | 2017-01-27 | 2022-02-01 | Trustees Of Tufts College | Nanocomplexes of polyanion-modified proteins |
| US12357580B2 (en) | 2018-06-19 | 2025-07-15 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids |
| WO2019246203A1 (en) * | 2018-06-19 | 2019-12-26 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle compositions for delivery of mrna and long nucleic acids |
| WO2020051220A1 (en) * | 2018-09-04 | 2020-03-12 | The Board of the Regents of the University of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
| AU2019336679B2 (en) | 2018-09-04 | 2025-05-29 | The Board Of Regents Of The University Of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
| AU2021252496A1 (en) * | 2020-04-06 | 2022-11-03 | Tiba Biotech Llc | Carriers for efficient nucleic acid delivery |
| CN117157101A (zh) | 2021-02-08 | 2023-12-01 | 德克萨斯大学系统董事会 | 不饱和的树枝状聚合物组合物、有关的制剂、及其使用方法 |
| WO2022192498A1 (en) * | 2021-03-11 | 2022-09-15 | Sinon Therapeutics Inc. | Carbon nanoparticle compositions and methods for delivering therapeutics to specific target sites |
| AU2022246065A1 (en) | 2021-03-22 | 2023-10-12 | Recode Therapeutics, Inc. | Compositions and methods for targeted delivery to cells |
| MX2023011243A (es) | 2021-03-23 | 2023-12-14 | Recode Therapeutics Inc | Composiciones de polinucleotidos, formulaciones relacionadas y metodos de uso de los mismos. |
| CN117500933A (zh) * | 2021-04-22 | 2024-02-02 | 德克萨斯大学系统董事会 | 能够实现精确的hdr介导的体内基因编辑的基于树枝状聚合物的全合一脂质纳米颗粒 |
| US20240252677A1 (en) * | 2021-05-24 | 2024-08-01 | The Trustees Of The University Of Pennsylvania | One-component delivery system for nucleic acids |
| JP2024543272A (ja) * | 2021-11-29 | 2024-11-20 | ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント | マルチモチーフデンドロン及びその超分子構造ならびにその使用 |
| IL317412A (en) | 2022-06-03 | 2025-02-01 | Bio Trip B V | Lipid nanoparticles based on multifunctional molecules for nucleic acid delivery |
| KR20250115452A (ko) | 2022-12-08 | 2025-07-30 | 리코드 테라퓨틱스, 인크. | 지질 나노입자 조성물 및 이의 용도 |
| US12121591B2 (en) | 2022-12-22 | 2024-10-22 | Nanovation Therapeutics Inc. | Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents |
| WO2025096681A1 (en) | 2023-10-31 | 2025-05-08 | Tiba Biotech Llc | Novel gene delivery agents |
| US12364773B2 (en) | 2023-12-01 | 2025-07-22 | Recode Therapeutics, Inc. | Lipid nanoparticle compositions and uses thereof |
Family Cites Families (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| JPS57125808A (en) | 1981-01-30 | 1982-08-05 | Nippon Chemiphar Co Ltd | Preparation of cephapyrine |
| JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
| US4558120A (en) * | 1983-01-07 | 1985-12-10 | The Dow Chemical Company | Dense star polymer |
| FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
| US4605735A (en) | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
| US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| US4824941A (en) | 1983-03-10 | 1989-04-25 | Julian Gordon | Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems |
| US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
| US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
| US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
| US5258506A (en) | 1984-10-16 | 1993-11-02 | Chiron Corporation | Photolabile reagents for incorporation into oligonucleotide chains |
| US4828979A (en) | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
| FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
| US4762779A (en) | 1985-06-13 | 1988-08-09 | Amgen Inc. | Compositions and methods for functionalizing nucleic acids |
| US5317098A (en) | 1986-03-17 | 1994-05-31 | Hiroaki Shizuya | Non-radioisotope tagging of fragments |
| JPS638396A (ja) | 1986-06-30 | 1988-01-14 | Wakunaga Pharmaceut Co Ltd | ポリ標識化オリゴヌクレオチド誘導体 |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| CA1340032C (en) | 1987-06-24 | 1998-09-08 | Jim Haralambidis | Lucleoside derivatives |
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
| DE3738460A1 (de) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | Modifizierte oligonukleotide |
| US5082830A (en) | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
| US5109124A (en) | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
| US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
| US5262536A (en) | 1988-09-15 | 1993-11-16 | E. I. Du Pont De Nemours And Company | Reagents for the preparation of 5'-tagged oligonucleotides |
| US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5599923A (en) | 1989-03-06 | 1997-02-04 | Board Of Regents, University Of Tx | Texaphyrin metal complexes having improved functionalization |
| US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| US5451463A (en) | 1989-08-28 | 1995-09-19 | Clontech Laboratories, Inc. | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides |
| US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
| US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
| US5292873A (en) | 1989-11-29 | 1994-03-08 | The Research Foundation Of State University Of New York | Nucleic acids labeled with naphthoquinone probe |
| US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
| US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
| US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
| US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
| US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
| US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
| AU7579991A (en) | 1990-02-20 | 1991-09-18 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
| US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| DE69032425T2 (de) | 1990-05-11 | 1998-11-26 | Microprobe Corp., Bothell, Wash. | Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5614617A (en) | 1990-07-27 | 1997-03-25 | Isis Pharmaceuticals, Inc. | Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression |
| US5688941A (en) | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| EP0556301B1 (en) | 1990-11-08 | 2001-01-10 | Hybridon, Inc. | Incorporation of multiple reporter groups on synthetic oligonucleotides |
| US5371241A (en) | 1991-07-19 | 1994-12-06 | Pharmacia P-L Biochemicals Inc. | Fluorescein labelled phosphoramidites |
| US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
| JP3739785B2 (ja) | 1991-11-26 | 2006-01-25 | アイシス ファーマシューティカルズ，インコーポレイティド | 修飾されたピリミジンを含有するオリゴマーを使用する増強された三重らせんおよび二重らせんの成形 |
| US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
| TW393513B (en) | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
| US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
| US5595726A (en) | 1992-01-21 | 1997-01-21 | Pharmacyclics, Inc. | Chromophore probe for detection of nucleic acid |
| US5272250A (en) | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
| EP0673559A1 (en) | 1992-12-14 | 1995-09-27 | Honeywell Inc. | Motor system with individually controlled redundant windings |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
| US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
| US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
| US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US6156564A (en) | 1996-06-07 | 2000-12-05 | The United States Of America As Represented By The Department Of Health And Human Services | Cellular apoptosis susceptibility protein (CSP) and antisense CSP |
| US6197787B1 (en) | 1997-03-03 | 2001-03-06 | Sanofi-Synthelabo | Pharmaceutical formulations containing poorly soluble drug substances |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| DE19743269A1 (de) | 1997-09-30 | 1999-04-01 | Siemens Ag | Herstellverfahren für eine Bi-haltige keramische Schicht |
| US6126995A (en) | 1997-09-30 | 2000-10-03 | The United States Of America As Represented By The Secretary Of The Navy | Process for producing stable divalent scandium |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| NZ506648A (en) | 1998-03-20 | 2003-08-29 | Benitec Australia Ltd | Control of gene expression through introduction of synthetic tandem repeats to reduce translation of mRNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| EP1071753A2 (en) | 1998-04-20 | 2001-01-31 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| US6199844B1 (en) | 1998-07-27 | 2001-03-13 | Chrysler Corporation | Striker cap for vehicle suspension system |
| US6098957A (en) | 1998-07-31 | 2000-08-08 | Honeywell Inc. | Electro-mechanical torque limiter for valve actuators |
| US6186231B1 (en) | 1998-11-20 | 2001-02-13 | Texaco Inc. | Conformance improvement in hydrocarbon bearing underground strata using lignosulfonate-acrylic acid graft copolymer gels |
| CN102180924A (zh) | 1999-05-04 | 2011-09-14 | 桑塔里斯制药公司 | L-核糖-lna类似物 |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6989574B2 (en) | 2000-08-24 | 2006-01-24 | Heetronix | High temperature circuit structures with thin film layer |
| US7053150B2 (en) * | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| US7314956B2 (en) * | 2001-08-08 | 2008-01-01 | Vaxim, Inc. | Multifunctional carrier for the delivery of a pharmacological agent or genetic material into a cell |
| JP2003181751A (ja) | 2001-12-17 | 2003-07-02 | Shirai Tekkosho:Kk | 板ガラスのエッジ面取機 |
| KR20030055020A (ko) | 2001-12-26 | 2003-07-02 | 주식회사 포스코 | 연주기 몰드 진동장치 |
| US6987930B2 (en) | 2002-08-27 | 2006-01-17 | Pentax Corporation | Lens barrel incorporating the advancing/retracting mechanism |
| AU2003291753B2 (en) | 2002-11-05 | 2010-07-08 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| WO2004044136A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2’-modified nucleosides for use in gene modulation |
| KR100916379B1 (ko) | 2003-01-10 | 2009-09-07 | 사천홍시현시기건유한공사 | 유기 전기발광 소자의 캐소드 패드 제조방법 |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| ATE555118T1 (de) | 2003-08-28 | 2012-05-15 | Takeshi Imanishi | Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung |
| JP5379347B2 (ja) | 2003-09-18 | 2013-12-25 | アイシス ファーマシューティカルズ， インコーポレーテッド | ４’−チオヌクレオシドおよびオリゴマー化合物 |
| US7985424B2 (en) * | 2004-04-20 | 2011-07-26 | Dendritic Nanotechnologies Inc. | Dendritic polymers with enhanced amplification and interior functionality |
| CA2564780C (en) * | 2004-04-20 | 2010-11-23 | Dendritic Nanotechnologies, Inc. | Dendritic polymers with enhanced amplification and interior functionality |
| KR101356935B1 (ko) * | 2004-05-05 | 2014-01-28 | 사일런스 테라퓨틱스 아게 | 지질, 지질 복합체 및 이들의 용도 |
| GB0422877D0 (en) * | 2004-10-14 | 2004-11-17 | Univ Glasgow | Bioactive polymers |
| JP5777846B2 (ja) | 2005-06-15 | 2015-09-09 | マサチューセッツ インスティテュート オブ テクノロジー | アミン含有脂質およびその使用 |
| TWI384032B (zh) * | 2005-12-21 | 2013-02-01 | Dendritic Nanotechnologies Inc | 具有增強的放大率及內部官能度的樹枝狀聚合物 |
| US20090221684A1 (en) * | 2005-12-22 | 2009-09-03 | Trustees Of Boston University | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof |
| JP5342881B2 (ja) | 2006-01-27 | 2013-11-13 | アイシス ファーマシューティカルズ， インコーポレーテッド | ６−修飾された二環式核酸類似体 |
| US7547684B2 (en) | 2006-05-11 | 2009-06-16 | Isis Pharmaceuticals, Inc. | 5′-modified bicyclic nucleic acid analogs |
| CA2658768C (en) | 2006-07-21 | 2016-05-17 | Massachusetts Institute Of Technology | End-modified poly(beta-amino esters) and uses thereof |
| US20080068922A1 (en) | 2006-09-12 | 2008-03-20 | Voss Klaus-W | Device for blending a binder component and a hardener component for producing a ready-made filler |
| KR20080039618A (ko) | 2006-11-01 | 2008-05-07 | 엘지전자 주식회사 | 이동통신 단말기의 데이터 서비스 방법 |
| WO2008101157A1 (en) | 2007-02-15 | 2008-08-21 | Isis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
| EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| US20080294089A1 (en) * | 2007-06-06 | 2008-11-27 | Biovaluation & Analysis, Inc. | Dendritic Polymers for Use in Acoustically Mediated Intracellular Drug Delivery in vivo |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| CA2692579C (en) | 2007-07-05 | 2016-05-03 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| EP2219680A2 (en) * | 2007-11-13 | 2010-08-25 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating protein expression |
| US8969353B2 (en) | 2008-11-07 | 2015-03-03 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| JP2012509258A (ja) * | 2008-11-17 | 2012-04-19 | エンゾン ファーマシューティカルズ，インコーポレーテッド | 核酸送達系のための分岐カチオン性脂質 |
| US8163861B2 (en) * | 2009-01-15 | 2012-04-24 | Living Proof, Inc. | Beta-amino ester compounds and uses thereof |
| AP2012006053A0 (en) | 2009-06-02 | 2012-02-29 | Brian Charles Keller | Pure peg-lipid conjugates. |
| CN101591428B (zh) | 2009-06-29 | 2011-05-25 | 浙江大学 | 一种聚酯树枝状大分子的制备方法 |
| MX341332B (es) * | 2010-06-03 | 2016-08-16 | Alnylam Pharmaceuticals Inc | Lipidos biodegradables para la administracion de agentes activos. |
| WO2012016184A2 (en) * | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| JP5136634B2 (ja) | 2010-12-17 | 2013-02-06 | オムロン株式会社 | 端子台装置 |
| WO2012090223A1 (en) | 2010-12-29 | 2012-07-05 | Indian Institute Of Science | Poly(ether imine) dendrimers and uses thereof |
| EP2998289B1 (en) | 2011-06-08 | 2019-08-07 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing sirna activity |
| JP6197787B2 (ja) | 2012-03-27 | 2017-09-20 | 株式会社ニコン | 振動アクチュエータ、レンズ鏡筒及び電子機器 |
| MY189533A (en) | 2012-05-25 | 2022-02-16 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| CA2881602A1 (en) | 2012-08-14 | 2014-02-20 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
| JP6241193B2 (ja) | 2012-10-23 | 2017-12-06 | コニカミノルタ株式会社 | 透明電極、電子デバイス及び有機エレクトロルミネッセンス素子 |
| JP6186231B2 (ja) | 2013-10-01 | 2017-08-23 | 株式会社日立製作所 | 鉄道車両用駆動システム |
| CN103999853B (zh) | 2014-06-11 | 2015-07-22 | 中国农业大学 | 荧光树枝状纳米大分子在制备药物载体中的应用 |
| JP6199844B2 (ja) | 2014-10-31 | 2017-09-20 | 日本電信電話株式会社 | 被疑箇所推定装置及び被疑箇所推定方法 |
| AU2015360794B2 (en) * | 2014-12-08 | 2021-07-08 | The Board Of Regents Of The University Of Texas System | Lipocationic polymers and uses thereof |
| CN116640316A (zh) * | 2015-09-14 | 2023-08-25 | 得克萨斯州大学系统董事会 | 亲脂阳离子树枝状聚合物及其用途 |
| PL3458074T3 (pl) * | 2016-05-16 | 2024-11-12 | Board Of Regents Of The University Of Texas System | KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA |
| JP6156564B1 (ja) | 2016-09-28 | 2017-07-05 | 株式会社メイショーテクノ | 試料設置台 |
| WO2019246203A1 (en) * | 2018-06-19 | 2019-12-26 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle compositions for delivery of mrna and long nucleic acids |
| WO2020051220A1 (en) * | 2018-09-04 | 2020-03-12 | The Board of the Regents of the University of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
| AU2022246065A1 (en) * | 2021-03-22 | 2023-10-12 | Recode Therapeutics, Inc. | Compositions and methods for targeted delivery to cells |
-
2016
- 2016-09-14 CN CN202310014834.7A patent/CN116640316A/zh active Pending
- 2016-09-14 ES ES16847193T patent/ES2899308T3/es active Active
- 2016-09-14 EP EP16847193.6A patent/EP3349802B1/en active Active
- 2016-09-14 KR KR1020187010292A patent/KR102641298B1/ko active Active
- 2016-09-14 CN CN201680065889.9A patent/CN108271360B/zh active Active
- 2016-09-14 JP JP2018513463A patent/JP7041616B2/ja active Active
- 2016-09-14 KR KR1020247006066A patent/KR102764250B1/ko active Active
- 2016-09-14 EP EP21183801.6A patent/EP3950003A1/en active Pending
- 2016-09-14 US US15/265,064 patent/US11247968B2/en active Active
- 2016-09-14 DK DK16847193.6T patent/DK3349802T3/da active
- 2016-09-14 PT PT16847193T patent/PT3349802T/pt unknown
- 2016-09-14 WO PCT/US2016/051648 patent/WO2017048789A1/en not_active Ceased
- 2016-09-14 CA CA2998473A patent/CA2998473A1/en active Pending
-
2021
- 2021-11-04 CY CY20211100954T patent/CY1125338T1/el unknown
- 2021-11-08 JP JP2021181987A patent/JP7496808B2/ja active Active
- 2021-12-30 US US17/566,666 patent/US11858884B2/en active Active
-
2023
- 2023-06-15 US US18/335,990 patent/US20240025848A1/en active Pending
- 2023-06-15 US US18/335,960 patent/US11999683B2/en active Active
- 2023-06-15 US US18/335,974 patent/US12024486B2/en active Active
- 2023-11-13 US US18/508,211 patent/US20240083842A1/en active Pending
- 2023-11-13 US US18/508,202 patent/US20240116860A1/en active Pending
- 2023-11-13 US US18/508,192 patent/US20240116859A1/en active Pending
-
2024
- 2024-05-28 JP JP2024085967A patent/JP2024122997A/ja active Pending
- 2024-08-12 US US18/800,894 patent/US20240391869A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537403A5 (enExample) | ||
| JP2022031692A5 (enExample) | ||
| US11464865B2 (en) | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | |
| US8772472B2 (en) | SiRNA conjugate and preparation method thereof | |
| ES2899043T3 (es) | Novedosos conjugados de oligonucleótidos y su uso | |
| ES2742654T3 (es) | Oligonucleótidos antisentido modificados hidrofóbicamente que comprenden un grupo cetal | |
| JPWO2020051220A5 (enExample) | ||
| JPWO2020051223A5 (enExample) | ||
| JP2023002587A (ja) | アンフィレグリン遺伝子特異的二重鎖オリゴヌクレオチド及びこれを含む線維症関連疾患及び呼吸器関連疾患の予防及び治療用組成物 | |
| KR101241852B1 (ko) | ｓｉＲＮＡ 접합체 및 그 제조방법 | |
| WO2017068791A1 (ja) | 少なくとも１つのバルジ構造を有する核酸複合体 | |
| JP7658900B2 (ja) | 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート | |
| KR101392973B1 (ko) | ｓｉＲＮＡ 접합체 및 그 제조방법 | |
| KR102575703B1 (ko) | Wfdc2의 발현을 조절하는 안티센스 화합물 | |
| US20250346891A1 (en) | Modified nucleic acid conjugates | |
| KR102613178B1 (ko) | Wfdc2의 발현을 조절하는 안티센스 화합물 | |
| AU2015200143A1 (en) | Sirna conjugate and preparation method thereof |